RxDoctor Payments Data

Jessica Foote

Primary Care · O Fallon, MONPI 1154066264

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 89 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 32.6% of the total. 2025 is the largest year on record at $1,035, 8.5 times the $122 reported in 2023.

$1,972in general payments, 2019–2025

Across 89 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$643
  • Novo Nordisk$421
  • Ironshore Pharmaceuticals Inc.$138
  • Pfizer$90
  • Procept Biorobotics Corporation$68
  • Lilly USA, LLC$65
  • plus $547 from 17 others

What the payments were for

  • Food & beverage$1,972100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,972 in reported general payments places this provider in the 75th percentile of 106 primary care providers in Missouri.

See all primary care providers in Missouri

Medicare billing

Part B allowed, 2024
$16,103
Medicare patients
67
Services billed
211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$25,137
Oxybutynin Chloride ErOxybutynin Chloride17$934
Omeprazole39$712
Atorvastatin Calcium101$575
Albuterol Sulfate HfaAlbuterol Sulfate28$524
Pravastatin Sodium19$410
Levothyroxine Sodium46$369
Ezetimibe17$329
Pantoprazole Sodium28$324
Duloxetine Hcl15$284
Fluticasone Propionate19$250
Losartan Potassium46$195
Gabapentin16$185
Amlodipine Besylate36$178
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav24$166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$421$25,13717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 106 primary care providers in Missouri.

Other primary care in O Fallon

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →